Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry

Main Article Content

Diamant Thaci
Alan Menter
Jashin J Wu
Dilek Arikan
Hartmut Kupper
Mareike Bereswill
Wendell C Valdecantos


psoriasis, adalimumab, biologic therapy


Abstract Not Available


Disclosures: Study supported by AbbVie.